Ziyuanyuan Holdings Group Limited (HKG:8223)
1.020
-0.090 (-8.11%)
Sep 29, 2025, 2:33 PM HKT
Ziyuanyuan Holdings Group Revenue
Ziyuanyuan Holdings Group had revenue of 207.11M CNY in the half year ending June 30, 2025, with 24.52% growth. This brings the company's revenue in the last twelve months to 525.30M, up 6.60% year-over-year. In the year 2024, Ziyuanyuan Holdings Group had annual revenue of 498.71M with 4.21% growth.
Revenue (ttm)
525.30M CNY
Revenue Growth
+6.60%
P/S Ratio
0.83
Revenue / Employee
4.20M CNY
Employees
125
Market Cap
477.30M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 498.71M | 20.13M | 4.21% |
Dec 31, 2023 | 478.57M | 173.20M | 56.72% |
Dec 31, 2022 | 305.37M | 196.11M | 179.49% |
Dec 31, 2021 | 109.26M | 60.48M | 123.97% |
Dec 31, 2020 | 48.78M | -4.88M | -9.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
JD Health International | 71.34B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |
WuXi Biologics | 21.98B |
Sino Biopharmaceutical | 33.49B |
Akeso | 2.75B |
Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |